THE STORY BEHIND
LIBI Diagnostics
STORY
LIBI Diagnostics is for you, it's for your loved ones, it is OUR venture. Together.
The story of our founder, and super dad, David Risin
My name is David Risin. Four-and-a-half years ago my wife and I were living the Israeli dream. We were happily married, had five beautiful children, my career was thriving.

Things suddenly changed. My sweet six-month-old daughter, Libby, was diagnosed with a rhabdoid tumour on her kidney. This form of cancer has almost no therapeutic information on how to treat it, and there is little-to-no chance of survival.
At that moment, I decided to dedicate my life to saving Libby. Nothing else mattered to me.
I left my career and frantically started to research this type of cancer and how we could beat it. I created a unique treatment protocol, just for her. When the team of doctors expressed opposition to a particular procedure, I had done my research so thoroughly that I was able to scientifically discuss it with them.

They ended up deciding to follow my innovative path. This was a life-changing moment, one that ended up being able to save my daughter's life.
They ended up deciding to follow my innovative path. This was a life-changing moment, one that ended up being able to save my daughter's life.
Today, Libby is an amazing 5-year old girl with a wonderful life ahead of her.
Today, the current method to detect recurrence is periodic imaging testing - which is very costly and entails much radiation. Therefore, these tests can only be done with large time intervals between them. Moreover, the imaging testing is less effective in detecting early-stage cancer cells

If the test gives a negative result, you can live until the next test. But if the test turns out to be positive, it means recurrence is already in progress. And as with all violent cancers, the cancer cells mutate and develop immunity to the therapies that were already given to the patient. The chances of survival decrease dramatically and in most cases, this recurrence ends in a fatality.

As part of my journey to find a solution, I researched and found that there is a technological possibility for developing such a body fluid test. I have recruitedProfessor Genjem Kalpanafrom The Albert Einstein University of Medicine in New York, an expert in genetics and immunology, as a partner, and these days she is heading up prototype development in accordance with FDA requirements.
In addition to Prof. Kalpana, Dr.Shiri Karni-Ashkenzi, a Ph.D. researcher at Rambam Hospital, has also joined the venture as a partner, and together we will bring a scientific breakthrough for cancer patients around the world.
The general good is a guideline at LIBI Diagnostics
The earlier the cancer is detected, the greater the chance of survival.

We pledge to do everything to make the LIBI test a standard in hospitals and thus save oncology patients the periodic examinations (MRI / CT), which give an indication of recurrence of the disease - too late!
our vision
Our vision is to make cancer an easy disease to treat. By early detection of cancer cells, we will shorten the duration of treatments, reduce their intensity and avoid unnecessary deaths. All this, by accessible means that can address patients around the world.
our mission
We pledge to make the LIBI Diagnostics an available standard test in healthcare institutions around the world to give an indication of the recurrence of cancer as early as possible before it develops to critical stages.
Milestones
1
The venture successfully completed the MaofTech acceleration program of the Israeli Ministry of Economy.
2
The venture is collaborating with Albert Einstein College of Medicine in New York to develop a non invasive method to detect and quantify AURKA gene mRNA over expression for AT/RT, MRT tumors by RNA FISH (fluorescent in situ hybridization) presented in voided presented in voided Urine samples.
3
The company received extensive media exposure and raised capital through a crowdfunding platform Headstart with more than 1,200 supporters.
4
The company has engaged with PWC to provide audit services and professional guidance in order to promote the company to financial excellence in the world of biotech startups.
5
The company has engaged with RC&P (Reinhold Cohn) to render intellectual property-related professional services and filling an International application PCT (International Patent).